Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS08 - Industry Symposium Sponsored by Janssen Oncology: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
- 13:00 - 14:00
- 1/29/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS08.02 - A Light at the End of the Tunnel - Hope for Patients With EGFR Exon20 Insertion Mutations
13:05 - 13:25 | Presenter: Byoung Chul Cho
- Abstract
No abstract available for this presentation
-
+
OA05 - Value and Quality in Lung Cancer
- 15:30 - 16:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Health Services Research/Health Economics
-
+
OA05.03 - Real-World Global Data on Targeting Epidermal Growth Factor Receptor in Stage III Non-Small Cell Lung Cancer: The Results of the KINDLE Study
15:30 - 15:40 | Presenter: Abdul Rahman Jazieh
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.05 - Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
14:25 - 14:30 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
14:35 - 14:40 | Presenter: Byoung Chul Cho
- Abstract
Loading...
-
+
ES30 - What is the Best Treatment Strategy to Target Rare Mutations
- 16:45 - 17:45
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Targeted Therapy - Clinically Focused
-
+
ES30.04 - Monoclonal Antibodies Targeting the ErbB Receptors
16:57 - 17:09 | Presenter: Byoung Chul Cho
- Abstract
Loading...
first
prev